KOSDAQBiotech & Pharma187660

Penetrium Bioscience

₩5,890▲ 7.88%2026-11-18 close
Market Cap
₩376.8B
Turnover
₩3.7B
Volume
630K
Shares out.
64M
PER
—
PBR
5.7×
EPS
-₩197
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

From CRO to novel drugs, with funding as the key variable

Revenue has declined for three consecutive years and operating losses have run for five straight quarters, while the cancer candidate Penetrium enters clinical testing on a smaller funding base than originally planned.

  1. 1

    Revenue fell from KRW 14.9 billion in 2022 to KRW 9.27 billion in 2025, declining for three consecutive years from 2023 to 2025.

  2. 2

    The operating loss peaked at KRW 15.9 billion in 2024 and narrowed to KRW 7.38 billion in 2025, with the operating margin improving from -163.5% to -79.5%.

  3. 3

    The operating loss in the third quarter of 2026 was KRW 2.67 billion, the largest of the last five quarters on a disclosed basis, and the attributable net loss over the last four quarters totaled KRW 10.6 billion.

  4. 4

    The 2026 rights offering raised about KRW 26.2 billion against a plan of roughly KRW 73.8 billion, and reports said the R&D allocation was cut from KRW 55 billion to KRW 20 billion.

  5. 5

    On the clinical side, the key milestones are the US FDA's approval of a Phase 2a IND in September 2026 and the MFDS approval of compassionate use for prostate cancer in November 2026.

02

Business structure

Penetrium Bioscience started as a contract research organization (CRO) founded in 2003, and after the largest shareholder changed in 2024 it has been widening its business toward novel drug development.

The business currently has two parts: clinical trial services that run trials for pharmaceutical and biotech companies, and Late Phase Service (LPS) work.

Clinical trial service revenue fell from KRW 11.9 billion in 2021 to KRW 3.9 billion in 2025, and reports said LPS revenue overtook trial service revenue in 2025 to account for more than half of total sales. As legacy CRO volume shrank, the emphasis shifted toward late-stage clinical capabilities.

In 2024 the company acquired an exclusive license from Hyundai Bioscience for anticancer uses of its Penetrium drug delivery platform in breast and lung cancer for KRW 9.1 billion, adding an in-house drug development business.

Penetrium is an oral candidate built on the idea of pseudo-resistance, in which the tumor microenvironment rather than the cancer cells themselves blocks anticancer drugs from reaching their targets. The indication strategy is moving from solid tumors toward rheumatoid arthritis.

In Korea, the largest shareholder is running a Phase 1 prostate cancer trial with Seoul National University Hospital, and in the United States the FDA approved a Phase 2a IND in September 2026 for relapsed or refractory advanced solid tumors. The product strategy centers on combining one candidate with multiple existing cancer drugs across tumor types.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.6B-₩1.5B−55.8%
2025Q4₩1.9B-₩1.6B−80.4%
2026Q1₩1.7B-₩1.8B−108.5%
2026Q2₩2.1B-₩1.9B−87.9%
2026Q3₩1.9B-₩2.7B−141.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩14.9B-₩800M₩300M−5.1%0.9%50.7%
2023₩13.8B-₩3.5B-₩3B−25.1%−10.9%63.0%
2024₩9.7B-₩15.9B-₩20.1B−163.5%−294.6%330.4%
2025₩9.3B-₩7.4B-₩14.8B−79.5%−68.9%52.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual results show both declining revenue and continued losses.

Revenue fell from KRW 14.9 billion in 2022 to KRW 13.8 billion in 2023 (down 7.3% year on year), KRW 9.74 billion in 2024 (down 29.3% year on year), and KRW 9.27 billion in 2025 (down 4.8% year on year); 2022 was the largest year between 2022 and 2025, and 2025 was the smallest.

Operating profit went from an operating loss of KRW 750 million in 2022 to KRW 3.46 billion in 2023 and KRW 15.9 billion in 2024, so the loss widened, and then it shrank to KRW 7.38 billion in 2025. The operating margin fell from -5.1% in 2022 to -163.5% in 2024, then improved to -79.5% in 2025.

It was reported that the larger loss in 2024 resulted from the revenue decline combined with the KRW 9.1 billion exclusive license contract payment being recognized as R&D expense. In 2025, even though revenue declined slightly, cost reductions were cited as the factor behind the smaller operating loss.

Net income attributable to controlling shareholders was KRW 270 million in 2022, then turned to a net loss attributable to controlling shareholders of KRW 2.97 billion in 2023, followed by a net loss of KRW 20.1 billion in 2024 and a net loss of KRW 14.8 billion in 2025.

Net income including non-controlling interests was a net loss of KRW 20.3 billion in 2024 and a net loss of KRW 14.8 billion in 2025, which differs from the figures attributable to controlling shareholders.

At the end of 2025, total equity was KRW 21.5 billion and total liabilities were KRW 11.3 billion, and the debt-to-equity ratio fell from 330.4% in 2024 to 52.3% in 2025.

It was reported that the conversion of convertible bonds and redeemable convertible preferred shares into common shares increased equity during this process. Operating cash flow was -KRW 3.08 billion in 2023, -KRW 14.3 billion in 2024, and -KRW 4.47 billion in 2025, so cash outflows continued.

On a quarterly basis, revenue fell from KRW 2.61 billion in the third quarter of 2025 to KRW 1.93 billion in the fourth quarter of 2025, rebounded to KRW 2.12 billion in the second quarter of 2026, and then fell to KRW 1.89 billion in the third quarter of 2026, down 27.4% from the same period a year earlier.

The operating loss widened from KRW 1.46 billion in the third quarter of 2025 to KRW 2.67 billion in the third quarter of 2026.

05

Industry analysis

The CRO business depends on clinical trial volumes from pharmaceutical and biotech companies. Reports attributed the fall in trial service revenue from KRW 11.9 billion in 2021 to KRW 3.9 billion in 2025 partly to fewer new project awards.

Headcount also fell about 33%, from 169 at the end of 2023 to 113 in the first quarter of 2026, according to reporting based on regulatory filings. In novel drug development, costs for patient recruitment and trial operations typically rise sharply as trials advance to later phases.

Anticancer drugs are a field where resistance to targeted therapies and treatment ceilings are shared challenges. The company's approach aims to modulate the tumor microenvironment around cancer cells so that existing drugs can reach them in combination.

The company describes this mechanism as non-immunosuppressive, selectively modulating the energy metabolism of diseased cells rather than suppressing the whole immune system. In 2026 the company presented nonclinical evidence at the World Conference on Lung Cancer and at ACR Convergence. Its position against other anticancer drug developers currently rests on nonclinical and early clinical data.

06

Outlook

The nearest clinical milestone is the US Phase 2a trial. On September 3, 2026, the FDA approved an IND for a Phase 2a multicenter study in relapsed or refractory advanced solid tumors, evaluating efficacy and safety in combination with standard anticancer drugs.

In September 2026 the chairman said the trials can proceed with current funding. In Korea, the first patient in the prostate cancer Phase 1 trial run by the largest shareholder with Seoul National University Hospital completed 12 weeks of dosing, and on November 16, 2026 the MFDS approved six months of additional use.

The company frames whether combination effects seen in nonclinical work also appear in patients as the central question of this trial. Earlier 2026 reporting said the company aimed to publish proof-of-concept data on overcoming pseudo-resistance by year-end 2026.

The rheumatoid arthritis indication is at an early stage after a license agreement signed with C&Pharm in early 2026. The fund use plan originally ran from the third quarter of 2026 through the second quarter of 2029, but the R&D allocation has been reduced following the smaller raise.

The next checkpoints are the timing of the first patient dosing in the US Phase 2a, progress of compassionate use in prostate cancer, and whether additional fundraising follows.

07

Valuation

PER
—
PBR
5.7×
ROE
-38.2%
EPS
-₩197
BPS
₩969
Dividend per share
₩0

The current PER cannot be calculated because the company has posted net losses over the last four quarters. The PBR sits in a range where the share price carries a large premium to book value, meaning the market value sits well above net assets.

However, equity at the end of 2025 rose because convertible bonds and redeemable preferred shares converted into common stock, so the book-value multiple should be read with that capital structure change in mind. The company pays no dividend, so a comparison based on dividend yield is not meaningful.

Reports said the largest shareholder has pledged a large portion of its shares, which is cited as a factor for shifts in ownership and share price volatility. Over 2024 and 2025 the stock was subject to eight market alert disclosures, including five investment caution notices and three investment warnings. Stock options covering 1.86 million shares are also cited as a potential source of dilution.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Entry into clinical stages and an indication expansion strategy

On September 3, 2026, the company disclosed that the US FDA approved an IND for a Phase 2a trial of Penetrium in advanced solid tumors.

In Korea, the first patient in the prostate cancer Phase 1 trial run by the largest shareholder completed 12 weeks of dosing, and on November 16, 2026 the MFDS approved six months of additional use. The company is pursuing an indication expansion strategy that combines the candidate with existing anticancer drugs.

A growing share of late-phase services

Reports said LPS revenue overtook trial service revenue in 2025 and accounted for more than half of total sales. Trial service revenue fell from KRW 11.9 billion in 2021 to KRW 3.9 billion in 2025, as the business weight moved toward late-phase capabilities.

The operating loss narrowed to KRW 7.38 billion in 2025 from KRW 15.9 billion in 2024, which shows an improvement on the cost side.

Support from the largest shareholder and funding routes

An April 2026 report said the largest shareholder, Hyundai Bioscience, decided to take up 100% of its allotted shares in the 2026 offering. A September 2026 report said the shareholder has invested a cumulative KRW 30.1 billion since 2024. The company said that clinical work can continue with current funding even after the smaller raise.

09

Bear factors

A smaller raise and cash pressure

The 2026 rights offering raised KRW 26.2 billion, only 35.4% of the planned amount. Reports said the R&D allocation was therefore cut from KRW 55 billion to KRW 20 billion.

Reports put cash and cash equivalents at about KRW 0.5 billion at the end of the second quarter of 2026, against KRW 5.0 billion in short-term borrowings.

Continued losses and falling sales

Third-quarter 2026 revenue was KRW 1.89 billion, down 27.4% year on year. The operating loss in the same quarter was KRW 2.67 billion, the largest of the last five quarters.

The attributable net loss over the last four quarters totaled KRW 10.6 billion, and reports said headcount fell from 169 at the end of 2023 to 113 in the first quarter of 2026.

Unverified efficacy and dilution risk

The anticancer effect of Penetrium rests on nonclinical data and conference presentations and still needs confirmation in patients. An April 2026 report said 850,000 of the 1.86 million outstanding stock options become exercisable from November 29, 2026. The 2026 offering involved 8.5 million new shares, equal to a 15.32% increase in shares.

10

Risk factors

Funding and dilution

The company did not fill much of its planned funding through the 2026 offering, and industry commentary points to the possibility of further fundraising. Reports said cash and equivalents were below short-term borrowings at the end of the second quarter of 2026.

The company has said R&D spending will rise as trials advance, so future funding needs could grow. Exercise of stock options could also increase the share count.

Clinical progress and efficacy verification

The prostate cancer Phase 1 trial is evaluating safety and tolerability, while the US Phase 2a is at the stage following IND approval. Nonclinical results are based on animal models and organoid studies, so whether the same effect appears in people is not yet established.

Costs for patient recruitment and trial operations tend to rise sharply as trials advance, which could increase the cost burden.

Governance and market volatility

Reports said the largest shareholder has pledged 62.5% of its holding, and the risk of forced sales of pledged shares is cited. Reports say the stock was subject to eight market alert disclosures during 2024 and 2025. The largest shareholder's stake fell from 30.82% in 2024 to 25.95% at the end of 2025.

11

What to watch next

  1. November 29, 2026

    The date when 850,000 stock options become exercisable. Actual exercise volume and the change in share count are the next items to track.

  2. End of 2026

    Whether the company publishes the pseudo-resistance proof-of-concept data it targeted for year-end 2026. The key question is whether nonclinical results carry over to patient data.

  3. Late March 2027

    The filing deadline for the 2026 annual report. Items to check include full-year 2026 revenue and operating results, R&D spending, cash and borrowings, and how the 2026 offering proceeds were used.

  4. Mid-May 2027

    The filing deadline for the Q1 2027 quarterly report. It will show whether the first US Phase 2a patient has been dosed, the progress of prostate cancer compassionate use, and cash at quarter end.

12

Overall view

Penetrium Bioscience is shifting its business axis toward novel anticancer drug candidates while its CRO revenue declines and losses continue. On a disclosed basis, revenue fell from KRW 14.9 billion in 2022 to KRW 9.27 billion in 2025, and the operating loss narrowed to KRW 7.38 billion in 2025 from 2024.

However, the operating loss in the third quarter of 2026 was KRW 2.67 billion, the largest of the last five quarters.

Factors on the bullish side include the US Phase 2a IND approval, compassionate use approval in the domestic prostate cancer trial, a rising share of late-phase services, and support from the largest shareholder.

Factors on the bearish side include a rights offering that raised only 35.4% of the planned amount and a resulting cut to R&D allocation, reports of tight cash and borrowings, efficacy that has not yet been confirmed in patients, and dilution from stock option exercises. These two sets of factors carry equal weight.

The next checkpoints are R&D spending and cash balances in the 2026 annual report and whether the first US trial patient is dosed. Option exercises after November 29, 2026 could change the share count, so that is also a point to track.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. newstomato.com
  3. greened.kr
  4. pharm.edaily.co.kr
  5. greened.kr
  6. medipana.com
  7. dealsite.co.kr
  8. v.daum.net
  9. view.asiae.co.kr
  10. kr.investing.com
  11. biotimes.co.kr
  12. news1.kr
  13. enewstoday.co.kr
  14. press9.kr
  15. m.news.nate.com
  16. fnnews.com
  17. m.news.nate.com
  18. fnnews.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis